Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Amortization of Deferred Charges (2016 - 2018)

GT Biopharma (GTBP) has disclosed Amortization of Deferred Charges for 7 consecutive years, with -$1.1 million as the latest value for Q4 2019.

  • On a quarterly basis, Amortization of Deferred Charges changed N/A to -$1.1 million in Q4 2019 year-over-year; TTM through Dec 2019 was -$266000.0, a N/A change, with the full-year FY2020 number at -$317000.0, changed N/A from a year prior.
  • Amortization of Deferred Charges was -$1.1 million for Q4 2019 at GT Biopharma, down from $669000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $6.9 million in Q1 2015 to a low of -$1.1 million in Q4 2019.
  • A 5-year average of $1.1 million and a median of $473000.0 in 2016 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: crashed 105.26% in 2015, then surged 103200.0% in 2016.
  • GT Biopharma's Amortization of Deferred Charges stood at $2.1 million in 2015, then tumbled by 103.06% to -$65000.0 in 2016, then soared by 3480.0% to $2.2 million in 2017, then plummeted by 69.55% to $669000.0 in 2018, then plummeted by 260.84% to -$1.1 million in 2019.
  • Per Business Quant, the three most recent readings for GTBP's Amortization of Deferred Charges are -$1.1 million (Q4 2019), $669000.0 (Q3 2018), and $141000.0 (Q2 2018).